MaxCyte Inc (MXCT) Ord USD0.01 (DI)
- Add to watchlist
- Create an alert
- This stock can be held in a
279.00p
284.00p
420.00p
£297.40 million
279.00p
279.00p
265.00p
n/a
4.00p (1.45%) Previous:
4.00p
19,784
n/a
750
Performance
1 week 1W | 4.12% | 1 year 1Y | 18.72% |
---|---|---|---|
1 month 1M | 4.78% | 2 years 2Y | 52.71% |
3 months 3M | 22.5% | 3 years 3Y | 63.1% |
6 months 6M | 5.42% | 5 years 5Y | 146.9% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue ($m) | 41.29 | 44.26 |
Profit before tax ($m) | (37.92) | (23.57) |
Adjusted EPS (¢): | (37.00) | (54.87) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
MaxCyte appoints new chief commercial officer
10 October 2024 13:23
-
MaxCyte enters licence agreement with Kamau Therapeutics
16 September 2024 11:22
-
MaxCyte reports solid second-quarter performance
7 August 2024 12:36
-
Exercise of options and PDMR dealing
31 October 2024 07:00
-
Grant of Options and Restricted Stock Units
18 October 2024 09:24
-
MaxCyte Appoints Cynthia Collins to Board
15 October 2024 13:05
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.